CDH1 and adenocarcinoma: Taken together, our experiments have shown that in vivo efficacy of the highly selective FAK inhibitor BI 853520 in mouse adenocarcinoma models is linked to a mesenchymal tumor phenotype characterized by low E-cadherin mRNA and protein levels and by low expression of miRNA hsa-miR-200c-3p.